NCT03087032 (LiraGooD) is a Phase 4 clinical trial of Liraglutide in Type 2 Diabetes Patients, sponsored by The First Affiliated Hospital of Xiamen University.

Who is sponsoring NCT03087032?

NCT03087032 is sponsored by The First Affiliated Hospital of Xiamen University.

What drugs are being tested in NCT03087032?

Interventions in NCT03087032: Liraglutide, insulin glargine.

What condition does NCT03087032 study?

NCT03087032 studies Type 2 Diabetes Patients, Overweight and Obesity, Hyperglycaemia (Diabetic).

Is NCT03087032 still recruiting?

NCT03087032 is currently recruiting now. Last updated 13 January 2025.

Last reviewed 2025-01-13 · How we verify

NCT03087032: LiraGooD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)

Recruiting now Phase 4 Last updated 13 January 2025

What this trial tests

Phase 4 trial testing Liraglutide in Type 2 Diabetes Patients in 164 participants. Currently enrolling.

Timeline

10 January 2019

Primary endpoint
15 January 2025

10 February 2025

Quick facts

Lead sponsor	The First Affiliated Hospital of Xiamen University
Phase	Phase 4
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	164
Start date	10 January 2019
Primary completion	15 January 2025
Estimated completion	10 February 2025
Sites	1 location across China

Drugs / interventions tested

Liraglutide (liraglutide) — full drug profile →
insulin glargine (INSULIN GLARGINE) — full drug profile →

Conditions studied

Type 2 Diabetes Patients — all drugs for Type 2 Diabetes Patients →
Overweight and Obesity — all drugs for Overweight and Obesity →
Hyperglycaemia (Diabetic) — all drugs for Hyperglycaemia (Diabetic) →

Sponsor

The First Affiliated Hospital of Xiamen University

Who can join

Adults 18 to 75, any sex, with Type 2 Diabetes Patients or Overweight and Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present 24-week, prospective, open-label, randomized, multicenter, parallel group trial is carried to investigate and evaluate the efficacy and safety of Liraglutide in combination with prandial insulin therapy vs insulin glargine in combination with prandial insulin therapy in overweight / obese patients with uncontrolled type 2 diabetes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Liraglutide

Trials testing the same drug.

NCT07225816 — Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in · Phase 1 · recruiting
NCT06818292 — Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists · NA · completed
NCT06283641 — Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan. · completed
NCT06501326 — Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease · Phase 4 · unknown
NCT05756764 — Anti-obesity Pharmacotherapy and Inflammation · active not recruiting

Other recruiting trials for Type 2 Diabetes Patients

Currently open trials in the same condition.

NCT07005986 — Role of Circulating Pyrophosphate as a Biomarker of Mediacalcinosis in Type 2 Diabetic Patients · NA · recruiting
NCT06769477 — The Effect of Education Given to Type 2 Diabetics on Diabetes Self-management, Health Fatalism and Metabolic Parameters · NA · recruiting

Other The First Affiliated Hospital of Xiamen University trials

Trials by the same sponsor.

NCT06875063 — GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL · Phase 1 · recruiting
NCT07486492 — Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer · EARLY_PHASE1 · not yet recruiting
NCT07458906 — DLL3-Targeted PET/CT in Neuroendocrine Carcinoma · NA · recruiting
NCT07137052 — Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinomar · not yet recruiting
NCT07189884 — Pyrotinib Maleate Tablets in Combination With Dalpiciclib Isethionate Tablets and Standard Endocrine Therapy · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03087032 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Xiamen University
Last refreshed: 13 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03087032.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing